These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27308632)

  • 1. Antitumor activity of LSD1 inhibitors in lung cancer.
    Mohammad HP; Kruger RG
    Mol Cell Oncol; 2016 Mar; 3(2):e1117700. PubMed ID: 27308632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
    Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
    Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
    Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
    J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.
    Yan W; Chung CY; Xie T; Ozeck M; Nichols TC; Frey J; Udyavar AR; Sharma S; Paul TA
    Mol Oncol; 2022 Mar; 16(6):1309-1328. PubMed ID: 34669238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer.
    Jotatsu T; Yagishita S; Tajima K; Takahashi F; Mogushi K; Hidayat M; Wirawan A; Ko R; Kanemaru R; Shimada N; Mitani K; Saito T; Takamochi K; Suzuki K; Kohsaka S; Kojima S; Mukae H; Yatera K; Takahashi K
    Biochem Biophys Rep; 2017 Mar; 9():86-94. PubMed ID: 28955993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
    Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
    Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.
    Macheleidt IF; Dalvi PS; Lim SY; Meemboor S; Meder L; Käsgen O; Müller M; Kleemann K; Wang L; Nürnberg P; Rüsseler V; Schäfer SC; Mahabir E; Büttner R; Odenthal M
    Mol Oncol; 2018 Nov; 12(11):1965-1979. PubMed ID: 30220105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer.
    Mandl A; Jasmine S; Krueger T; Kumar R; Coleman IM; Dalrymple SL; Antony L; Rosen DM; Jing Y; Hanratty B; Patel RA; Jin-Yih L; Dias J; Celatka CA; Tapper AE; Kleppe M; Kanayama M; Speranzini V; Wang YZ; Luo J; Corey E; Sena LA; Casero RA; Lotan T; Trock BJ; Kachhap SK; Denmeade SR; Carducci MA; Mattevi A; Haffner MC; Nelson PS; Rienhoff HY; Isaacs JT; Brennen WN
    bioRxiv; 2024 Jan; ():. PubMed ID: 38328141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.
    Lim S; Janzer A; Becker A; Zimmer A; Schüle R; Buettner R; Kirfel J
    Carcinogenesis; 2010 Mar; 31(3):512-20. PubMed ID: 20042638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
    Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
    J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
    Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
    Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.
    Wang S; Zhao LJ; Zheng YC; Shen DD; Miao EF; Qiao XP; Zhao LJ; Liu Y; Huang R; Yu B; Liu HM
    Eur J Med Chem; 2017 Jan; 125():940-951. PubMed ID: 27769034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.
    Schulte JH; Lim S; Schramm A; Friedrichs N; Koster J; Versteeg R; Ora I; Pajtler K; Klein-Hitpass L; Kuhfittig-Kulle S; Metzger E; Schüle R; Eggert A; Buettner R; Kirfel J
    Cancer Res; 2009 Mar; 69(5):2065-71. PubMed ID: 19223552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of [1,2,3]Triazolo[4,5-
    Li ZH; Liu XQ; Geng PF; Suo FZ; Ma JL; Yu B; Zhao TQ; Zhou ZQ; Huang CX; Zheng YC; Liu HM
    ACS Med Chem Lett; 2017 Apr; 8(4):384-389. PubMed ID: 28435523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.